Breaking News, Collaborations & Alliances

Sanofi Pasteur, CureVac Extend mRNA Vax Pact

Sanofi exercises its options on five pathogens

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

CureVac, a German biopharma company, has entered an exclusive license agreement with Sanofi Pasteur S.A., the vaccines division of Sanofi, to develop and commercialize an mRNA-based vaccine for an undisclosed target.   Sanofi Pasteur will fund all R&D, manufacturing and commercialization activities and will have exclusive worldwide marketing rights for the RNActive vaccine. CureVac will receive an upfront and additional payment for extending the option term for the other pathogens. CureVac i...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters